Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Awakn Life Sciences Corp (AWKNF)

Awakn Life Sciences Corp (AWKNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Awakn Life Sciences Discusses Filing of Financial Statements Newsfile - Thu May 2, 5:16PM CDT

Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.1268 (+0.32%)
AWKN.CN : 0.1700 (+6.25%)
Awakn Life Sciences Announces Closing of Tranche of Private Placement Newsfile - Wed Apr 17, 6:34AM CDT

Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.1268 (+0.32%)
AWKN.CN : 0.1700 (+6.25%)
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic Newsfile - Wed Apr 3, 6:32AM CDT

Awakn also announces Private PlacementToronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology...

AWKNF : 0.1268 (+0.32%)
AWKN.CN : 0.1700 (+6.25%)
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange Newsfile - Mon Feb 12, 6:46AM CST

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.1268 (+0.32%)
AWKN.CN : 0.1700 (+6.25%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Announces Conditional Approval of CSE Listing Newsfile - Mon Feb 5, 6:36AM CST

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers Newsfile - Wed Jan 24, 6:36AM CST

Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US MarketToronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"),...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS Newsfile - Wed Dec 20, 2023

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents Filed in US and Key International MarketsToronto, Ontario--(Newsfile...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Provides Corporate Update Newsfile - Fri Dec 15, 2023

Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001 Newsfile - Wed Nov 15, 2023

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto, Ontario--(Newsfile Corp. - November...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements Newsfile - Fri Nov 10, 2023

Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing therapeutics to treat...

AWKNF : 0.1268 (+0.32%)
AWKN.NE : 0.1100 (-21.43%)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside Barchart - Sat May 4, 2:45PM CDT
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot